Researchers are exploring in vivo site-specific engineering to reprogram T cells, which may hold promise for cell therapy. However, early trials have reportedly caused serious toxicities in patients. The approach is part of a broader field of cell therapy advancements, including direct cell reprogramming and chimeric-antigen-receptor-T-cell therapy, which are being studied for their potential benefits and challenges.